Aptevo Therapeutics Stock Price, News & Analysis (NASDAQ:APVO) $0.20 +0.01 (+5.32%) (As of 11:40 AM ET) Add Compare Share Share Today's Range$0.19▼$0.2050-Day Range$0.18▼$0.3852-Week Range$0.15▼$7.20Volume148,221 shsAverage Volume253,138 shsMarket Capitalization$3.52 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Aptevo Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.15% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.78) to ($1.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.80 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Aptevo Therapeutics. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.15% of the outstanding shares of Aptevo Therapeutics have been sold short.Short Interest Ratio / Days to CoverAptevo Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aptevo Therapeutics has recently decreased by 74.21%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAptevo Therapeutics does not currently pay a dividend.Dividend GrowthAptevo Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for APVO. Previous Next 3.3 News and Social Media Coverage News SentimentAptevo Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Aptevo Therapeutics this week, compared to 0 articles on an average week.Search Interest5 people have searched for APVO on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Aptevo Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aptevo Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.70% of the stock of Aptevo Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 8.06% of the stock of Aptevo Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Aptevo Therapeutics are expected to grow in the coming year, from ($1.78) to ($1.33) per share.Price to Book Value per Share RatioAptevo Therapeutics has a P/B Ratio of 0.07. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aptevo Therapeutics Stock (NASDAQ:APVO)Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and. ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers. Its preclinical candidates include APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; APVO711, a dual mechanism bispecific ADAPTIR candidate designed to provide synergistic stimulation of CD40 on antigen presenting cells; and APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Read More APVO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APVO Stock News HeadlinesDecember 4, 2023 | americanbankingnews.comAptevo Therapeutics (NASDAQ:APVO) Now Covered by StockNews.comNovember 29, 2023 | americanbankingnews.comAptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Down 74.2% in NovemberDecember 4, 2023 | Edge On The Street (Ad)Is This The Most Overlooked Gold Investment Strategy of 2024?There is little debate on the potential of gold in the next year and decade. The real issue becomes - what's the best gold investment strategy today? Some investors are opting for a unique "royalty" alternative that outshines other options like holding gold bullion or investing in volatile mining stocks.November 27, 2023 | americanbankingnews.comAptevo Therapeutics (NASDAQ:APVO) Coverage Initiated by Analysts at StockNews.comNovember 22, 2023 | msn.comAptevo Therapeutics files to sell up to 32.03M shares of common stock for holdersNovember 14, 2023 | msn.comAptevo Therapeutics GAAP EPS of -$0.50November 14, 2023 | finance.yahoo.comAptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business UpdateNovember 1, 2023 | finanznachrichten.deAptevo Therapeutics: Aptevo to Present at Bio-Europe ConferenceDecember 4, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 1, 2023 | finance.yahoo.comAptevo to Present at Bio-Europe ConferenceOctober 21, 2023 | thestreet.comWith New Cash Aptevo Goes It Alone on Prostate Drug, Shares Up - Biotech MoversSeptember 26, 2023 | money.usnews.comAptevo Therapeutics IncAugust 10, 2023 | finance.yahoo.comAptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business UpdateAugust 4, 2023 | finance.yahoo.comAptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public OfferingAugust 3, 2023 | msn.comAptevo Therapeutics (APVO) Price Target Increased by 24.14% to 18.36August 2, 2023 | benzinga.comWhy Aptevo Therapeutics Stock Is Getting ObliteratedAugust 2, 2023 | investorplace.comWhy Is Aptevo Therapeutics (APVO) Stock Down 33% Today?August 2, 2023 | msn.comAptevo Therapeutics down 25% after pricing $5M offeringAugust 2, 2023 | finance.yahoo.comAptevo Therapeutics Inc. Announces Pricing of $5 Million Public OfferingJuly 18, 2023 | finanznachrichten.deAptevo Therapeutics: Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AMLJuly 18, 2023 | benzinga.comAptevo Therapeutics Stock Is Sinking Today - Here's WhyJune 29, 2023 | ca.finance.yahoo.comAPVO - Aptevo Therapeutics Inc.May 11, 2023 | finance.yahoo.comAptevo Therapeutics Reports 1Q23 Financial Results and Provides Business UpdateApril 1, 2023 | finance.yahoo.comAptevo Therapeutics Full Year 2022 Earnings: EPS Beats ExpectationsMarch 30, 2023 | finance.yahoo.comAptevo Therapeutics Raises $9.6 Million in Non-Dilutive FundingMarch 30, 2023 | finance.yahoo.comAptevo Therapeutics Reports 2022 Financial Results and Provides Business UpdateJanuary 9, 2023 | finance.yahoo.comAptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid TumorsSee More Headlines Receive APVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptevo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2023Today12/04/2023Fiscal Year End12/31/2023Next Earnings (Estimated)4/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APVO CUSIPN/A CIK1671584 Webwww.aptevotherapeutics.com Phone(206) 838-0500Fax206-838-0503Employees45Year Founded2016Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$8.03 million Net MarginsN/A Pretax MarginN/A Return on Equity-97.61% Return on Assets-56.28% Debt Debt-to-Equity RatioN/A Current Ratio3.09 Quick Ratio3.09 Sales & Book Value Annual Sales$3.11 million Price / Sales1.08 Cash FlowN/A Price / Cash FlowN/A Book Value$0.84 per share Price / Book0.23Miscellaneous Outstanding Shares17,620,000Free Float16,965,000Market Cap$3.35 million OptionableNot Optionable Beta4.94 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Marvin L. White (Age 61)President, CEO & Director Comp: $892.86kMr. Jeffrey G. Lamothe CA (Age 57)Executive VP & COO Comp: $691.37kMs. SoYoung Kwon J.D.LL.M., Senior VP, General Counsel, Business Development & Corporate AffairsMs. Daphne L. Taylor (Age 57)Senior VP & CFO Dr. Jane A. Gross Ph.D. (Age 66)Chief Scientific Officer Comp: $515.17kDr. Dirk Huebner M.D. (Age 60)Chief Medical Officer More ExecutivesKey CompetitorsNeptune Wellness SolutionsNASDAQ:NEPTObsEvaNASDAQ:OBSVAridis PharmaceuticalsNASDAQ:ARDSFirst Wave BioPharmaNASDAQ:FWBIChina PharmaNYSE:CPHIView All CompetitorsInstitutional OwnershipSabby Management LLCBought 1,334,169 shares on 11/15/2023Ownership: 11.581%Armistice Capital LLCBought 1,235,000 shares on 11/15/2023Ownership: 10.717%View All Institutional Transactions APVO Stock Analysis - Frequently Asked Questions Should I buy or sell Aptevo Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APVO shares. View APVO analyst ratings or view top-rated stocks. How have APVO shares performed in 2023? Aptevo Therapeutics' stock was trading at $2.32 on January 1st, 2023. Since then, APVO shares have decreased by 91.4% and is now trading at $0.20. View the best growth stocks for 2023 here. Are investors shorting Aptevo Therapeutics? Aptevo Therapeutics saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 26,900 shares, a drop of 74.2% from the October 31st total of 104,300 shares. Based on an average daily volume of 483,200 shares, the days-to-cover ratio is presently 0.1 days. View Aptevo Therapeutics' Short Interest. When is Aptevo Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our APVO earnings forecast. How were Aptevo Therapeutics' earnings last quarter? Aptevo Therapeutics Inc. (NASDAQ:APVO) posted its quarterly earnings results on Tuesday, November, 14th. The biotechnology company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.14. What other stocks do shareholders of Aptevo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Advanced Micro Devices (AMD), Amarin (AMRN), AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Micron Technology (MU), OPKO Health (OPK), AbbVie (ABBV), Aurinia Pharmaceuticals (AUPH), BioXcel Therapeutics (BTAI) and T2 Biosystems (TTOO). Who are Aptevo Therapeutics' major shareholders? Aptevo Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Sabby Management LLC (11.58%), Armistice Capital LLC (10.72%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Aptevo Therapeutics? Shares of APVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:APVO) was last updated on 12/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptevo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.